Related Experiment Video
Updated: May 18, 2026
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Real-world clinical validation study: individualized warfarin dosing strategy integrating genetic polymorphisms and
Pu Bai1, Cunfa Shi2, Peitao Xie3
1Department of Pharmacy, Ordos Central Hospital, No. 6 Sudu Street, Kangbashi District, Ordos, 017010, China.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|May 16, 2026
Summary
Bayesian pharmacogenomic-guided dosing significantly improved warfarin therapy compared to conventional methods. This precision dosing approach accelerated therapeutic targets and reduced adverse events, enhancing patient safety and treatment efficacy.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Internal Medicine
Background:
- Warfarin dosing is complex, influenced by genetic and clinical factors.
- Conventional warfarin dosing relies on clinical judgment and INR monitoring, often leading to delayed therapeutic effects and suboptimal outcomes.
- Pharmacogenomic-guided dosing offers a personalized approach to optimize warfarin therapy.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of Bayesian pharmacogenomic-guided dosing for warfarin.
- To compare Bayesian pharmacogenomic-guided dosing with conventional dosing strategies.
Main Methods:
- A randomized controlled trial involving 60 patients, divided into Bayesian pharmacogenomic-guided dosing (n=30) and conventional dosing (n=30) groups.
- Bayesian pharmacogenomic-guided dosing utilized a pharmacokinetic-pharmacodynamic model incorporating demographic, clinical, and genetic variables.
- Conventional dosing relied on clinical judgment and INR monitoring.
Main Results:
- The Bayesian pharmacogenomic-guided dosing group achieved a significantly shorter time to first therapeutic INR (7.71 vs. 19.18 days, P<0.01).
- Higher rates of stable anticoagulation were observed in the Bayesian group (90% within 3 weeks vs. 33.3%, P<0.01).
- The percentage of time in therapeutic INR range was significantly higher (86.8% vs. 16.77%, P<0.001), with a lower incidence of adverse events (3.33% vs. 40.0%, P<0.01).
Conclusions:
- Bayesian pharmacogenomic-guided dosing significantly enhances anticoagulation precision and accelerates the achievement of therapeutic targets.
- This model-informed precision dosing strategy improves warfarin efficacy and safety compared to conventional empirical management.
- Implementation of Bayesian pharmacogenomic-guided dosing is supported for clinical practice to optimize patient outcomes.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...